Navigation Links
Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
Date:3/15/2012

DUBLIN, March 15, 2012 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets.

  • A strategic step in building Shire's hematology business (which already includes Xagrid and a growing development pipeline)
  • Adds a differentiated product in development (iron chelator FBS0701), with global rights, in a global market currently worth over $900 million and growing(1)
  • Serves chronic patient need for treatment of iron overload following numerous blood transfusions.  Excess iron in vital organs such as the liver and heart increases the risk of organ failure and is the principal cause of death in transfusion-dependent patients(2)
  • Consistent with Shire strategy of developing and commercializing differentiated specialist products prescribed by specialist physicians (hematologists/ hematologist-oncologists) served by a small sales force
  • FBS0701 will be developed to demonstrate clinical efficacy and an attractive safety profile relative to currently approved chelating agents:
  • Global filing planned for indications for Myelodysplastic Syndrome and hemoglobinopathies initially
  • Phase 2 studies underway with additional trials planned

    SOURCE Shire plc
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
    2. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
    3. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
    4. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
    5. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
    6. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
    7. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
    8. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
    9. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
    10. Reportlinker Adds Shire plc: PharmaVitae Profile
    11. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... , July 30, 2014  Decision Resources ... and medical directors in the United ... of biosimilar market penetration will be the level ... (MCOs) and the expected lower cost to patients. ... biosimilars that meet their pricing expectations in order ...
    (Date:7/30/2014)... 2014  Replikins Ltd. today released new data on ... Before the current outbreaks, the mean Ebola Reston gene ... between 1995 and 2002 was 1.1; the mean Replikin ... sixteen-fold in 2013, thus predicting the current outbreaks in ... been shown to be able to predict outbreaks (1). ...
    (Date:7/30/2014)... (PRWEB) July 30, 2014 Sales Horizons, ... launch of blended sales training programs for companies engaged ... training programs used by thousands of salespeople over 25 ... sales training program can be customized to address the ... The blended sales training program consists of ...
    (Date:7/30/2014)... (PRWEB) July 30, 2014 July 30, ... @APDN), a biotechnology firm that provides DNA-based authentication and ... Hogan, Ph.D. Vice President of Life Sciences, a newly ... , Dr. Hogan will lead APDN’s drive to ... relationships with biotech and healthcare customers, provide guidance to ...
    Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3
    ... Ryan MILWAUKEE - Watts Wacker, hippie extraordinaire and rock-star ... birthday bash last week. I was floored by his ... notes. Here's what Watts offered, along with some R-squared ... 200 Christians. When Paulone of JC's disciplesfinally laid down, ...
    ... August, those seven days in which we attempt to pack all ... For me, this week also signals the calm before the storm. ... 2004. (Its a great lineup, so if you haven't grabbed your ... should be polishing my opening comments and prepping my introductions, but ...
    ... are millions of very expensive, well-designed websites all over ... offer with great graphic illustrations, supportive explanations about their ... in a very large majority of cases, what is ... people behind the site: the owners, the management the ...
    Cached Biology Technology:Watts Up 2Wrapping up the Summer 2Wrapping up the Summer 3Wrapping up the Summer 4Whats Hush-Hush Marketing? 2Whats Hush-Hush Marketing? 3
    (Date:7/31/2014)... as the Rim Fire was in full fury, raging ... it entered the backcountry of Yosemite National Park in ... the park, the battle began to turn, enacting a ... can combine to fuel large, severe fires. , "When ... lands where fire had been used as a management ...
    (Date:7/31/2014)... with Hibiscus flowers- they are an iconic symbol ... planted in the landscape. Some, like Hawaii,s State ... , Only a relatively few botanists and Hawaiian ... beautiful and intriguing related group of plants known ... , Brother of Hibiscus species are in fact ...
    (Date:7/31/2014)... White, brown and beige adipocytes, or fat cells, are ... functions and each plays its own role in metabolism. ... far the most prevalent. Its primary function is energy ... energy to generate heat but are only found in ... adipocytes, which represent a special type of brown adipocytes, ...
    Breaking Biology News(10 mins):The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5Brother of Hibiscus is found alive and well on Maui 2Hope for the overweight 2
    ... Edition: , , New hope for tapping vast domestic reserves ... to use in the U. S. , Toward a fast, ... proteins identified in the quest for male contraceptive, Toward more ... Resources: , Press releases, chat room sessions, and more ...
    ... The National Institutes of Health announced today that it ... NIH Director,s Pioneer and New Innovator Awards to 47 ... of their careers. The grants, estimated to be up ... pursue exceptionally innovative approaches that could transform biomedical and ...
    ... are thought to be involved in colon cancer but the ... have discovered that a molecule produced by a common gut ... The research, published in the October issue of the ... gut bacteria can cause colon cancer. There are more ...
    Cached Biology News:ACS PressPac -- Sept. 17, 2008 2ACS PressPac -- Sept. 17, 2008 3ACS PressPac -- Sept. 17, 2008 4ACS PressPac -- Sept. 17, 2008 5ACS PressPac -- Sept. 17, 2008 6ACS PressPac -- Sept. 17, 2008 7ACS PressPac -- Sept. 17, 2008 8NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 2NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 3NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 4NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 5NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 6NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 7NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 8NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 9Cancer-causing gut bacteria exposed 2
    Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
    ...
    Mouse monoclonal antibody to ALAS2 - aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia)...
    ... of an N-terminal FLAG® fusion and a ... from bicistronic mRNA. Two genes can ... transcription of a single message from the ... protein-protein interaction studies, multi-subunit proteins, and cloning ...
    Biology Products: